From March 20 to 22, Dr. Schwartz, CEO of Roche Group Severin Schwan) attended the China Development Forum for the first time and offered advice through the conference.
Hosted by the Development Research Center of the State Council and hosted by the China Development Research Foundation, the China Development Forum aims to "dialogue with the world and seek common development", and is an important dialogue platform between senior leaders of the Chinese government, global business leaders, international organizations and Chinese and foreign scholars.
As a biotechnology leader, Roche has a 125-year history and has accumulated rich industry experience in more than 100 countries around the world. Rooted in China for more than 90 years, Roche Group has been committed to China for more than 90 years and has continuously invested in the Chinese market, bringing first-class differentiated drugs and medical solutions to Chinese patients, and is committed to becoming a partner in China's move towards the forefront of global biomedical innovation. At the forum, Dr. Schwan shared the following views:
1. Healthcare is an essential investment for all countries, and strong and resilient health systems will not only be effective against outbreaks, but will also help us tackle major chronic diseases such as cancer. Health not only boosts people's well-being, it also helps drive economic growth and social prosperity.
2. The pandemic has highlighted the value of diagnosis and demonstrated that we need good testing infrastructure. Testing and screening make early intervention possible, and a more defensive health care system not only saves costs, but also avoids a lot of suffering.
3. The epidemic has highlighted the value of medical data, and the development of information technology has given data great potential in solving difficult medical and health problems. With China's focus on technology and its pioneering approach to healthcare data, we firmly believe that China will become one of the world's leading innovation hubs.
At the same time, Dr. Shi Wan also submitted a report on the theme of "Accelerating the Transformation of Pharmaceutical Innovation and Empowering New Opportunities for Healthy China Construction", put forward Roche suggestions on the two major topics of "medical data application" and "biomedical industry innovation", and provided suggestions for supporting the implementation of the Healthy China Strategy and promoting high-quality social and economic development.
"Roche has witnessed remarkable development in China over the decades and is the first company to establish a complete pharmaceutical value industry chain in China." Dr. Schwan said, "Today, as the world's largest biotechnology company and in vitro diagnostic leader, we will continue to invest more in China. At the same time, we also look forward to working with the Chinese government, medical and health institutions, and local partners to jointly contribute to the ambitious goals of Healthy China 2030 and create a better future for the Chinese people. ”
Source: Guangming Network